Title: A Meta-analysis of pramipexole in Parkinson's disease
Abstract:Objective In comparative trials a meta-analysis was performed to compare the efficacy and adverse events of pramipexole and placebo as reported in the peer-reviewed medical literature.Methods We syste...Objective In comparative trials a meta-analysis was performed to compare the efficacy and adverse events of pramipexole and placebo as reported in the peer-reviewed medical literature.Methods We systematically reviewed the medical literature to identify randomized controlled trials of pramipexole and placebo used in the management of Parkinson's disease.Computerised databases(including Cochrane Central Register of Controlled Trials(CENTRAL),Medline(1966~2009),Embase(1974~2009)and Chinese National Knowledge Infrastructure database(CNKI))were used to identify pertinent articles for inclusion in this study.Randomized controlled trials published in the English and Chinese literature comparing the effect of pramipexole with placebo in Parkinson's Disease were eligible for inclusion.Two investigators independently assessed the quality and extracted the data.Results Six randomized controlled with a total number of 898 in pramipexole group and 813 in placebo group was identified.By Meta-analysis of all studies,we concluded there is an obvious decrease of endpoints(UPDRS Ⅱ,UPDRS Ⅲ and responder rate)in pramipexole group.No significant publication bias was found,funnel plots did not suggest evidence of significant bias.Meta-analysis of adverse events of pramipexole compared to placebo indicated OR1 for dyskinesia,dizziness,hallucination,somnolence,insomnia,nausea 1,which meant pramipexole may induce these adverse events.However,there were no significant differences in the incidence of orthostatic hypotension between the two groups.Conclusion Pramipexole is a efficacious and promising option in the treatment of paitient with Parkison`s disease.Pramipexole can be used to improve motor impairments and disability,but it can also increase the incidence of hallucination,somnolence,insomnia and some other adverse events.Further studies are needed to compare this dopamine agonist directly with existing therapies to elucidate its role in the PD treatment.Read More
Publication Year: 2010
Publication Date: 2010-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot